Photodynamic Therapy for Mesothelioma
Todd Demmy, MD, clinical chair, Department of Thoracic Surgery, professor of oncology, Roswell Park Cancer Institute, discusses photodynamic therapy for the treatment of mesothelioma.
Todd Demmy, MD, clinical chair, Department of Thoracic Surgery, professor of oncology, Roswell Park Cancer Institute, discusses photodynamic therapy for the treatment of mesothelioma.
Clinical Pearls:
- With photodynamic therapy, patients are given a drug that concentrates in tumor cells. A special light is then used to active the chemical, which kills the tumor cell.
- This therapy is useful for diseases that are hard to treat surgically and is currently being used to treat mesothelioma
- After a tumor is removed from a mesothelioma patient, the photodynamic agent photofrin is given to the patient and photodynamic therapy is performed to treat the microscopic cancer that is left behind
- This reduces the stress and complications of surgery that are usually associated with mesothelioma surgery
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
